An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
Status: Recruiting
Location: See all (8) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
• Able to take oral medication
• If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
• Adequate organ function and electrolytes
Locations
United States
Massachusetts
Dana-Farber Cancer Institute
RECRUITING
Boston
Michigan
University of Michigan
RECRUITING
Ann Arbor
Missouri
Washington University School of Medicine
RECRUITING
St Louis
Ohio
Cleveland Clinic
RECRUITING
Cleveland
Pennsylvania
Fox Chase Cancer Center
RECRUITING
Philadelphia
Tennessee
Vanderbilt- Ingram Cancer Center
RECRUITING
Nashville
Texas
NEXT Oncology, Austin
RECRUITING
Austin
NEXT Oncology, San Antonio
RECRUITING
San Antonio
Contact Information
Primary
Clinical Team
clinicaltrials@deciphera.com
888-724-3274
Time Frame
Start Date: 2025-08-27
Estimated Completion Date: 2029-02
Participants
Target number of participants: 60
Treatments
Experimental: DCC-2812
Participants will receive DCC-2812 in dose escalation manner per dosing regimen depending upon evolving pharmacokinetic (PK), pharmacodynamic, and safety data.
Related Therapeutic Areas
Sponsors
Leads: Deciphera Pharmaceuticals, LLC